ES2930298T3 - Moduladores del receptor de glucocorticoides de azadecalina condensada con heteroaril-cetona - Google Patents
Moduladores del receptor de glucocorticoides de azadecalina condensada con heteroaril-cetona Download PDFInfo
- Publication number
- ES2930298T3 ES2930298T3 ES21154665T ES21154665T ES2930298T3 ES 2930298 T3 ES2930298 T3 ES 2930298T3 ES 21154665 T ES21154665 T ES 21154665T ES 21154665 T ES21154665 T ES 21154665T ES 2930298 T3 ES2930298 T3 ES 2930298T3
- Authority
- ES
- Spain
- Prior art keywords
- receptor modulators
- glucocorticoid receptor
- fused azadecalin
- heteroaryl ketone
- azadecalin glucocorticoid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940117965 Glucocorticoid receptor modulator Drugs 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000003676 Glucocorticoid Receptors Human genes 0.000 abstract 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Electroluminescent Light Sources (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651669P | 2012-05-25 | 2012-05-25 | |
| US201261691083P | 2012-08-20 | 2012-08-20 | |
| US201261715907P | 2012-10-19 | 2012-10-19 | |
| US201361759520P | 2013-02-01 | 2013-02-01 | |
| US201361781629P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2930298T3 true ES2930298T3 (es) | 2022-12-09 |
Family
ID=49624542
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES21154665T Active ES2930298T3 (es) | 2012-05-25 | 2013-05-24 | Moduladores del receptor de glucocorticoides de azadecalina condensada con heteroaril-cetona |
| ES13793417.0T Active ES2665338T3 (es) | 2012-05-25 | 2013-05-24 | Moduladores del receptor de glucocorticoides de azadecalina condensada con heteroaril-cetona |
| ES18154256T Active ES2753816T3 (es) | 2012-05-25 | 2013-05-24 | Moduladores del receptor de glucocorticoides de azadecalina condensada con heteroaril-cetona |
| ES19188885T Active ES2873949T3 (es) | 2012-05-25 | 2013-05-24 | Moduladores del receptor de glucocorticoides de azadecalina condensada con heteroaril-cetona |
| ES22193438T Active ES2995026T3 (en) | 2012-05-25 | 2013-05-24 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13793417.0T Active ES2665338T3 (es) | 2012-05-25 | 2013-05-24 | Moduladores del receptor de glucocorticoides de azadecalina condensada con heteroaril-cetona |
| ES18154256T Active ES2753816T3 (es) | 2012-05-25 | 2013-05-24 | Moduladores del receptor de glucocorticoides de azadecalina condensada con heteroaril-cetona |
| ES19188885T Active ES2873949T3 (es) | 2012-05-25 | 2013-05-24 | Moduladores del receptor de glucocorticoides de azadecalina condensada con heteroaril-cetona |
| ES22193438T Active ES2995026T3 (en) | 2012-05-25 | 2013-05-24 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
Country Status (24)
| Country | Link |
|---|---|
| EP (6) | EP3851107B1 (enExample) |
| JP (1) | JP6172871B2 (enExample) |
| KR (1) | KR102062640B1 (enExample) |
| CN (1) | CN104619328B (enExample) |
| AU (1) | AU2013266110C1 (enExample) |
| BR (1) | BR112014028857B1 (enExample) |
| CA (1) | CA2872260C (enExample) |
| CL (1) | CL2014003173A1 (enExample) |
| DK (5) | DK2854814T3 (enExample) |
| ES (5) | ES2930298T3 (enExample) |
| FI (1) | FI4119561T3 (enExample) |
| HK (1) | HK1250014B (enExample) |
| IL (1) | IL235868A (enExample) |
| MX (1) | MX365423B (enExample) |
| MY (1) | MY172739A (enExample) |
| NZ (1) | NZ701469A (enExample) |
| PE (1) | PE20150352A1 (enExample) |
| PH (1) | PH12014502584A1 (enExample) |
| PL (5) | PL3590517T3 (enExample) |
| PT (5) | PT4119561T (enExample) |
| RU (1) | RU2639867C2 (enExample) |
| SG (1) | SG11201407682TA (enExample) |
| WO (1) | WO2013177559A2 (enExample) |
| ZA (1) | ZA201408182B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US12226412B2 (en) | 2012-05-25 | 2025-02-18 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US10047082B2 (en) | 2013-11-25 | 2018-08-14 | Corcept Therapeutics, Inc. | Octahydro fused azadecalin glucocorticoid receptor modulators |
| AU2016226451B2 (en) * | 2015-03-02 | 2019-12-19 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor antagonist and somatostatin analogues to treat ACTH-secreting tumors |
| KR102495223B1 (ko) * | 2015-03-30 | 2023-02-01 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 부신기능부전을 치료하기 위한 글루코코르티코이드와 조합된 글루코코르티코이드 수용체 길항제의 용도 |
| JP6755264B2 (ja) | 2015-05-18 | 2020-09-16 | コーセプト セラピューティクス， インコーポレイテッド | クッシング症候群についての処置を診断および評価するための方法 |
| WO2017027851A1 (en) * | 2015-08-13 | 2017-02-16 | Corcept Therapeutics, Inc. | Method for differentially diagnosing acth-dependent cushing's syndrome |
| AU2017228329B2 (en) * | 2016-03-01 | 2021-03-11 | Corcept Therapeutics, Inc. | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors |
| US9943505B2 (en) | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
| PT3600282T (pt) | 2017-03-31 | 2025-11-05 | Corcept Therapeutics Inc | Moduladores de recetores de glucocorticoides para tratar cancro cervical |
| AU2018289307B2 (en) | 2017-06-20 | 2024-02-01 | Corcept Therapeutics, Inc. | Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators |
| US10494349B2 (en) * | 2018-04-23 | 2019-12-03 | Corcept Therapeutics, Inc. | Methods of preparing regioselective N-alkyl triazoles |
| SG11202104732UA (en) | 2018-11-09 | 2021-06-29 | Corcept Therapeutics Inc | Methods for shrinking pituitary tumors |
| US11464764B2 (en) | 2018-12-19 | 2022-10-11 | Corcept Therapeutics Incorporated | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| WO2020132046A1 (en) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| CN113194944A (zh) * | 2018-12-20 | 2021-07-30 | 科塞普特治疗公司 | 用于对生长抑素受体阳性肿瘤进行成像和治疗的方法 |
| CN113490496A (zh) | 2019-02-22 | 2021-10-08 | 科赛普特治疗学股份有限公司 | 一种杂芳基-酮稠合氮杂萘烷糖皮质激素受体调节剂瑞拉可兰的治疗用途 |
| US12440487B2 (en) | 2019-10-16 | 2025-10-14 | Corcept Therapeutics Incorporated | Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonist |
| WO2021119432A1 (en) | 2019-12-11 | 2021-06-17 | Corcept Therapeutics Incorporated | Methods of treating antipsychotic-induced weight gain with miricorilant |
| EP4076470B1 (en) | 2019-12-21 | 2025-12-03 | Corcept Therapeutics Incorporated | Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome |
| WO2021163058A1 (en) * | 2020-02-10 | 2021-08-19 | Corcept Therapeutics Incorporated | Methods of stimulating an anti-tumor response using a selective glucocorticoid receptor modulator |
| WO2022134033A1 (en) * | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| WO2022166810A1 (zh) * | 2021-02-03 | 2022-08-11 | 江苏恒瑞医药股份有限公司 | 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用 |
| WO2024077169A1 (en) * | 2022-10-06 | 2024-04-11 | Corcept Therapeutics Incorporated | Formulations of glucocorticoid receptor modulators |
| EP4608402A1 (en) | 2022-10-28 | 2025-09-03 | Corcept Therapeutics Incorporated | Treatments for amyotrophic lateral sclerosis using dazucorilant |
| US20250360125A1 (en) * | 2023-02-17 | 2025-11-27 | Corcept Therapeutics Incorporated | Methods and compositions for treating huntington's disease and its symptoms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| GB8828669D0 (en) * | 1988-12-08 | 1989-01-11 | Lilly Industries Ltd | Organic compounds |
| WO2005087769A1 (en) * | 2004-03-09 | 2005-09-22 | Corcept Therapeutics, Inc. | Fused ring azadecalin glucocorticoid receptor modulators |
| US7640389B2 (en) | 2006-02-28 | 2009-12-29 | Freescale Semiconductor, Inc. | Non-volatile memory having a multiple block erase mode and method therefor |
| EP1932843A1 (en) * | 2006-12-14 | 2008-06-18 | sanofi-aventis | Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals |
| CN103080108A (zh) * | 2010-08-27 | 2013-05-01 | 科赛普特治疗公司 | 吡啶基-胺稠合的氮杂萘烷调节剂 |
-
2013
- 2013-05-24 EP EP21154665.0A patent/EP3851107B1/en active Active
- 2013-05-24 DK DK13793417.0T patent/DK2854814T3/en active
- 2013-05-24 AU AU2013266110A patent/AU2013266110C1/en active Active
- 2013-05-24 PT PT221934383T patent/PT4119561T/pt unknown
- 2013-05-24 PL PL19188885T patent/PL3590517T3/pl unknown
- 2013-05-24 PL PL13793417T patent/PL2854814T3/pl unknown
- 2013-05-24 ES ES21154665T patent/ES2930298T3/es active Active
- 2013-05-24 CA CA2872260A patent/CA2872260C/en active Active
- 2013-05-24 MX MX2014014239A patent/MX365423B/es active IP Right Grant
- 2013-05-24 PL PL22193438.3T patent/PL4119561T3/pl unknown
- 2013-05-24 DK DK21154665.0T patent/DK3851107T3/da active
- 2013-05-24 PT PT211546650T patent/PT3851107T/pt unknown
- 2013-05-24 EP EP22193438.3A patent/EP4119561B1/en active Active
- 2013-05-24 PT PT191888858T patent/PT3590517T/pt unknown
- 2013-05-24 PT PT181542564T patent/PT3338781T/pt unknown
- 2013-05-24 EP EP24192650.0A patent/EP4434584A3/en active Pending
- 2013-05-24 EP EP18154256.4A patent/EP3338781B1/en active Active
- 2013-05-24 DK DK22193438.3T patent/DK4119561T3/da active
- 2013-05-24 ES ES13793417.0T patent/ES2665338T3/es active Active
- 2013-05-24 KR KR1020147036405A patent/KR102062640B1/ko active Active
- 2013-05-24 MY MYPI2014003289A patent/MY172739A/en unknown
- 2013-05-24 PL PL21154665.0T patent/PL3851107T3/pl unknown
- 2013-05-24 FI FIEP22193438.3T patent/FI4119561T3/fi active
- 2013-05-24 ES ES18154256T patent/ES2753816T3/es active Active
- 2013-05-24 DK DK19188885.8T patent/DK3590517T3/da active
- 2013-05-24 SG SG11201407682TA patent/SG11201407682TA/en unknown
- 2013-05-24 NZ NZ701469A patent/NZ701469A/en unknown
- 2013-05-24 EP EP13793417.0A patent/EP2854814B1/en active Active
- 2013-05-24 ES ES19188885T patent/ES2873949T3/es active Active
- 2013-05-24 ES ES22193438T patent/ES2995026T3/es active Active
- 2013-05-24 CN CN201380039218.1A patent/CN104619328B/zh active Active
- 2013-05-24 PT PT137934170T patent/PT2854814T/pt unknown
- 2013-05-24 BR BR112014028857-7A patent/BR112014028857B1/pt active IP Right Grant
- 2013-05-24 EP EP19188885.8A patent/EP3590517B1/en active Active
- 2013-05-24 PL PL18154256T patent/PL3338781T3/pl unknown
- 2013-05-24 DK DK18154256T patent/DK3338781T3/da active
- 2013-05-24 JP JP2015514233A patent/JP6172871B2/ja active Active
- 2013-05-24 PE PE2014002054A patent/PE20150352A1/es active IP Right Grant
- 2013-05-24 RU RU2014152625A patent/RU2639867C2/ru active
- 2013-05-24 WO PCT/US2013/042732 patent/WO2013177559A2/en not_active Ceased
-
2014
- 2014-11-10 ZA ZA2014/08182A patent/ZA201408182B/en unknown
- 2014-11-19 PH PH12014502584A patent/PH12014502584A1/en unknown
- 2014-11-21 CL CL2014003173A patent/CL2014003173A1/es unknown
- 2014-11-23 IL IL235868A patent/IL235868A/en active IP Right Grant
-
2018
- 2018-07-23 HK HK18109510.2A patent/HK1250014B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2930298T3 (es) | Moduladores del receptor de glucocorticoides de azadecalina condensada con heteroaril-cetona | |
| CR20140479A (es) | Moduladores del receptor del estrogeno y sus usos | |
| PH12016500968B1 (en) | Octahydro fused azadecalin glucocorticoid receptor modulators | |
| PT3406609T (pt) | Compostos aza biciclicos como agonistas de recetores muscarínico | |
| DK3030581T3 (da) | Antistofbindingssteder, der er specifikke for egfrviii | |
| CL2017001987A1 (es) | Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1 | |
| EA201891209A1 (ru) | Модуляторы хемокиновых рецепторов | |
| MX377610B (es) | Agonistas del receptor de glucagon. | |
| EP3442971C0 (en) | ESTROGEN RECEPTOR MODULATORS | |
| CL2015002125A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
| EP2970281A4 (en) | SUBSTITUTED BENZOL COMPOUNDS | |
| HUE042226T2 (hu) | Ütemezéskérési eljárás D2D kommunikációhoz | |
| CL2015002609A1 (es) | 2-azabiciclos sustituidos y su uso como moduladores de rectores de orexina. | |
| MX2016014890A (es) | Agonistas del receptor de apelina (apj) y usos de los mismos. | |
| LT3377483T (lt) | N-pakeistieji indolo dariniai kaip pge2 receptoriaus moduliatoriai | |
| MX2017000182A (es) | Compuestos de pirazol como moduladores de fshr y usos de los mismos. | |
| DK3265459T3 (da) | Amidforbindelser som 5-ht4-receptoragonister | |
| CR20150008A (es) | Indolecarbonitrilos como moduladores selectivos recptores de androgeno | |
| HRP20181203T1 (hr) | Novi agonisti adrenergičkog receptora alfa2 | |
| EP3405455A4 (en) | 2-oxindole CONNECTIONS | |
| CL2015000359A1 (es) | Compuestos derivados de pirrolopirazoles sustituidos, bloqueadores del canal de calcio tipo n; y composicion farmaceutica que los comprende. | |
| DK3145916T3 (da) | Imidazolderivater som formylpeptidreceptormodulatorer | |
| CL2016001488A1 (es) | Quinazolin-thf-aminas como inhibidores de pde1 | |
| IL259418A (en) | Triarylmethane compound, a dye compound for staining the ocular membrane | |
| DK3072874T3 (da) | Hidtil ukendt fremgangsmåde til depolymerisering af lignin |